Income statement
USD
Annual
| Metric | 2024 | 2023 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17K | -25K | -1K | -2K | -87K |
| EBITDA | -17K | 89K | -1K | -2K | -87K |
| Net Income | -17K | -79K | -1K | -2K | -87K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.2952
-37.20% today
1Y Change
+112.38%
Window
Jun 26, 2025 → Jun 25, 2026
Coverage: 252 bars · Jun 26, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NDT Pharmaceuticals Inc. (NDTP) is a Healthcare stock with a market cap of $90.00M and listed on OTC. The stock last traded around $0.30 and up 112.4% across the available one-year price window (Jun 26, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +300.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +300.0%, free cash flow 0.0% with operating margin 0.0% and ROIC -49.5%. Stock Foundry combines NDTP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NDTP
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NDTP Max Drawdown
-84.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NDTP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$87.3K
-4427.2% YoY
Free Cash Flow
-$30.6K
+22.5% YoY
Revenue Growth
+0.0%
EPS Growth
+300.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17K | -25K | -1K | -2K | -87K |
| EBITDA | -17K | 89K | -1K | -2K | -87K |
| Net Income | -17K | -79K | -1K | -2K | -87K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|
| Cash & Equivalents | 647 | 0 | 67 | 2K | 89K |
| Total Assets | 143K | 50K | 50K | 52K | 139K |
| Total Liabilities | 42K | 359K | 358K | 357K | 355K |
| Shareholder Equity | 101K | -309K | -308K | -305K | -216K |
| Total Debt | 0 | 350K | 350K | 350K | 350K |
| Net Debt | -647 | 350K | 350K | 348K | 261K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
31K
+22.5% YoY
Capital Expenditures
0
Free Cash Flow
31K
+22.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.